Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Purtill, Duncan  [Clear All Filters]
2024
Atsuta Y, Baldomero H, Neumann D, Sureda A, DeVos JD, Iida M, Karduss A, Purtill D, Elhaddad AM, Bazuaye NG, et al. Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors. Haematologica. 2024.
Malherbe JAJ, Boan P, Purtill D, Wright M, Cannell P, Gangatharan SA, Sidiqi H, Cooney J. COVID-19 outcomes in haemopoietic stem cell transplant recipients in Western Australia: the value of vaccination and antiviral therapy. Intern Med J. 2024.
John TD, Maron G, Abraham A, Bertaina A, Bhoopalan SVelan, Bidgoli A, Bonfim C, Coleman Z, Dezern A, Li J, et al. Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. Cytotherapy. 2024.
2023
Pereira EYimei, Cannell PKenneth, Cooney J, Wright M, Herrmann B, Purtill D. Bariatric surgery and allogeneic hematopoietic stem cell transplantation: a case series. Bone Marrow Transplant. 2023.
Moore J, Hamad N, Gottlieb DJ, Bajel A, Ritchie DS, Yeung DT, Greenwood M, Purtill D, Tran S, Solterbeck A, et al. Early cessation of calcineurin inhibitors is feasible post haploidentical blood stem cell transplant-the ANZHIT-1 study. Blood Adv. 2023.
Belbachir S, Abraham A, Sharma A, Prockop S, DeZern AE, Bonfim C, Bidgoli A, Li J, Ruggeri A, Bertaina A, et al. Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2023.
Garcia-Rosa M, Abraham A, Bertaina A, Bhoopalan SVelan, Bonfim C, Cohen S, Dezern A, Louis C, Oved J, Pavel-Dinu M, et al. International society for cell & gene therapy stem cell engineering committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. Cytotherapy. 2023.
Smallbone P, Louw A, Purtill D. Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis. Pathology. 2023.
Kaur R, Purtill D, Cooney J, Cannell P, Wright M, Copeland T-S, McGuire M, Boan P. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation. Transpl Infect Dis. 2023:e14147.
Klein OR, Bonfim C, Abraham A, Ruggeri A, Purtill D, Cohen S, Wynn R, Russell A, Sharma A, Ciccocioppo R, et al. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. Cytotherapy. 2023.
2015
le Viellez A, P'Ng S, Buffery S, Wright M, Cooney J, Cannell P, Purtill D. Red cell and platelet transfusion burden following myeloablative allogeneic haematopoietic stem cell transplantation. Intern Med J. 2015.